NTIC
BCAX

Napean Trading & Investment Company’s Bicara Therapeutics BCAX Stock Holding History

Napean Trading & Investment Company’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38M Hold
113,780
– – 1.16% 6
2026
Q1 		$2.26M Hold
113,780
– – 0.97% 12
2025
Q4 		$1.91M Sell
113,780
-162,162
-59% -$2.77M 0.37% 35
2025
Q3 		$4.36M Hold
275,942
– – 0.85% 31
2025
Q2 		$2.56M Hold
275,942
– – 0.68% 31
2025
Q1 		$3.6M Buy
+275,942
New +$3.66M 1.05% 33

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Napean Trading & Investment Company's BCAX Position: Q2 2026 in Review

Napean Trading & Investment Company held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 113,780 shares worth $3.38M. The position accounts for 1.16% of the portfolio, ranked #6.

Napean Trading & Investment Company first reported a position in BCAX in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.36M in Q3 2025. 170 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Napean Trading & Investment Company held 113,780 shares of Bicara Therapeutics worth $3.38M as of Q2 2026.
  • Napean Trading & Investment Company left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up 1.16% of Napean Trading & Investment Company's portfolio in Q2 2026, its #6 holding.
  • Napean Trading & Investment Company first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Napean Trading & Investment Company's Bicara Therapeutics position peaked at $4.36M in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Napean Trading & Investment Company's 13F filing for Q2 2026, filed 12 Aug 2026.